CANCER
MANAGEMENT
I want to know
if I might have a
METASTATIC CANCER NOW
I want to know
my CANCER RISK
NOW and in the FUTURE
I want to know my
CANCER RISK in the FUTURE
by Circulating Tumor Cells (CTC)
Cancer is a non-communicable disease with a high worldwide incidence and mortality rate.
The National Cancer Institute of Thailand reports increasing cumulative incidence of breast, colorectal, lung and prostate cancers, accounting for more than 60% of all cancers in Thailand.
Cancer is consequently one of the most challenging public health issues in Thailand and the need for effective and easily accessible screening tools is apparent.
Most cancer deaths occur as a result of metastatic disease. Consequently, cancer patients are monitored for metastatic disease by periodic surveillance using clinical findings, biomarkers, and radiologic imaging techniques (computerized tomography [CT], positron emission tomography [PET], magnetic resonance imaging [MRI], etc.). A new method of monitoring patients with breast, colorectal, or prostate cancer includes detection of circulating tumor cells (CTC).
More than 100,000 such tests are performed annually in the US alone.
Our CellSearch CTC assay is the first and only assay to date cleared by the FDA for CTC analysis to determine prognosis in patients with metastatic breast, prostate, and colon cancers. The assay allows the capture and enumeration of tumor cells circulating in peripheral blood in a standardized format (1).
Clinical trials have shown that this type of testing offers useful and prognostic information for the physician to monitor progression of disease or response to treatment.
Studies have also demonstrated that detection and quantitation of CTC at any time during the course of disease is an independent predictor of progression-free and overall survival in patients with metastatic cancer and provides valuable prognostic information sooner to support patient care decisions (2-4).
Do Not Waste TIME!
Healthy persons without a cancer diagnosis should not have detectable CTC in their blood.
CTC appearance precedes appearance of cancer disease in imaging with an average of 2.8 years (5). CTC detection increase the risk for cancer recurrence 13-fold compared to no CTC detection (5).
Do not waste valuable time with blunt screening instruments like conventional imaging and tumor markers.
A simple blood test to perform a liquid biopsy offers the most informative tool available to oncologists today.
THAI StemLife
offers two different types of
CTC technologies.
Both require minute amounts of blood.
Our latest FX-CTC method will soon be able to offer single cell genetic testing to determine the origin
of the CTC and the tumor’s sensitivity
to cytostatic treatments.
Ask us for more details.
Clin Cancer Res
2004;10(20):6897-6904
N Engl J Med
2004;351(8):781-791
Clin Cancer Res
2008;14(19):6302-6309
J Clin Oncol
2008;26(19):3213-3221
JAMA Oncol.
2018 Dec 1;4(12):1700-1706
